پديدآورندگان :
Kamali Morteza Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran , J. Webster Thomas School of Health Sciences and Biomedical Engineering, Hebei University, Tijian, China UFPI - Universidade Federal do Piauí, Brazil, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India , Amani Amir Universidade Federal do Piauí, Brazil , Hadjighassem Mahmoud Reza Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran , Malekpour Mohammad Reza Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran , Tirgar Fatemeh Department of Neuroscience and Addiction Studies, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran , Khosravani Masood Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran , Adabi Mahdi Department of Medical Nanotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran, Food Microbiology Research Center, Tehran University of Medical Sciences, Tehran, Iran
چكيده فارسي :
Aim and Background: The aim of this study was to prepare folate-targeted Erlotinib loaded human serum albumin nanoparticles (FA-ERL-HSA NPs) and investigate in vitro cytotoxic and apoptotic effects using cell lines (U87MG and C6 cells) and an in vivo rat bearing C6 glioma model. Methods: the FA-ERL-HSA NPs prepared using a desolvation method and evaluated on U87,C6 and rat bearing glioma model. Conclusion: The mean size of the FA-ERL-HSA NPs was 135 nm. In vitro MTT assays demonstrated that FA-ERL-HSA NPs had an IC50 value of 52.18 μg/mL and 17.53 μg/mL compared to free ERL which had an IC50 value of 119.8 μg/mL and 103.2 μg/mL for U87MG and C6 cells for 72 h, respectively. Flow cytometry results showed the apoptosis rate with FA-ERL-HSA NPs (100 μg/mL, 72 h) was higher compared to free ERL for both U87MG and C6 cells. Experiments using a rat glioblastoma model via TUNEL assay indicated that the apoptosis index of FA-ERL-HSA NPs was 48 % compared to 21 % for free ERL and the tumor size effectively decreased after a daily injection of 220 μg (2.5 mg/kg) from 87.45 mm3 (19th day) to 1.28 mm3 (60th day). The median survival rate of the rats increased after treatment to 100 days which was greater than controls.
